Expression and Clinical Significance of HER3 in Breast Carcinoma
-
摘要: 目的 探讨乳腺癌患者HER3与HER2、ER和PR之间的关系及其对乳腺癌预后的影响。方法采用免疫组织化学SP法检测癌组织中HER3、HER2、ER和PR蛋白的表达，对患者随访，随访终点为总生存时间(overall survival,OS)。结果 HER2、HER3、ER和PR在136例乳腺癌患者中的阳性表达率分别为:50%、41.18%、60.9%和27.21%。HER3与年龄、淋巴结转移、分期、肿瘤类型以及化疗状态的差异无统计学意义(P>0.05)。HER3阳性与阴性患者OS差异有统计学意义(P=0.015)。HER3(+)HER2(+)组乳腺癌患者较其他组OS明显缩短(P=0.047)。HER3的表达与PR表达无明显关系(P=0.214)，但可抑制ER产生(P=0.001)。HER2阳性和HER3的过度表达高度相关(P=0.000)。结论HER3可作为独立的临床预后因子，HER3阴性患者OS较长。Abstract: Objective To investigate the relationships between the expression of HER3,HER2,ER and PR,and their effects on the clinical prognosis of human breast carcinoma. Methods The expressions of HER3,HER2,ER and PR were studied in 136 cases with breast carcinoma by using SP immunohistochemistry.The endpoint was overall survival(OS). Results HER2,HER3,ER and PR expression was detected in 136 cases with positive rates of 50%,41.18%,60.9% and 27.21%,respectively.The expression intensity of HER3 in breast carcinoma had no significant correlation with the age,lymph node metastasis,pathological types,TNM stage,chemotherapy of the patients(P>0.05).Compared with those patients with HER3-negitive profiles,the patients with HER3-positive profiles had significantly lower OS(P=0.015).The patients with HER3(+)HER2(+) expression profiles had significantly lower OS(P=0.047) than other groups.There is no interaction between HER3 and PR expression(P=0.214)，but HER3 have a inverse relationship with ER expression(P=0.001).Overexpression of HER2 and HER3 was highly correlated(P=0.000). Conclusion HER3 expression is an independent predictor of breast cancer.Patients with HER3-negative have a longer OS. Key words：
-
Key words:
- HER3 /
- HER2 /
- Breast carcinoma /
- Immunohistochemistry
-
-
[1] Zeng YX.Oncology[M].Beijing:People′s Medical Publishing House,2004:1130.[曾益新.肿瘤学[M].北京:人民卫生出版社，2004:1130.] [2] Karamouzis MV,Badra FA,Papavassiliou AG.Breast cancer:The upgraded role of HER-3 and HER-4[J].Int J Biochem Cell Biol,2007,39(5):851-6. [3] Soltoff SP,Carraway KL 3rd,Prigent SA,et al.ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor[J].Mol Cell Biol,1994,14(6):3550-8. [4] Barnes DM,Harris WH,Smith P,et al.Immunohistochemical determination of oestrogen receptor comparison of different methods of staining and correlation with clinical outcome of breast cancer[J].Br J Cancer,1996,74(9):1445-51. [5] Gullick WJ.The type 1 growth factor receprors and their ligands considered as a complex system[J].Endocr Ralat Cancer,2001,8(2):75-82. [6] Holbro T,Beerli RR,Maurer F,et al.The ErbB2/ErbB3 heterodimer functions as an oncogenic unit:ErbB2 requires ErbB3 to drive breast tumor cell proliferation[J].Proc Natl Acad Sci U S A,2003,100(15):8933-8. [7] Witton CJ,Reeves JR,Going JJ,et al.Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer[J].J Pathol,2003,200(3):290-7. [8] Bièche I,Onody P,Tozlu S,et al.Prognostic value of ERBB family mRNA expression in breast carcinomas[J].Int J Cancer,2003,106(5):758-65. [9] Lee Y,Cho S,Seo JH,et al.Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast[J].Am J Clin Pathol,2007,128(6):1041-9. [10] Lane HA,Beuvink I,Motoyama AB,et al.ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation:receptor overexpression does not determine growth dependency[J].Mol Cell Biol,2000,20(9):3210-23. [11] Barnes NL,Khavari S,Boland GP,et al.Absence of HER4 expression predicts recurrence of ductal carcinomas in situ of the breast[J].Clin Cancer Res,2005,11(6):2163-8. [12] Narayan M,Wilken JA,Harris LN,et al.Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells[J].Cancer Res,2009,69(6):2191-4. [13] Sergina NV,Rausch M,Wang D,et al.Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3[J].Nature,2007,445(7126):437-41.
计量
- 文章访问数: 5633
- HTML全文浏览量: 19
- PDF下载量: 595
下载:
